| __timestamp | Biogen Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2232342000 | 11606000000 |
| Thursday, January 1, 2015 | 2113100000 | 10313000000 |
| Friday, January 1, 2016 | 1947900000 | 9762000000 |
| Sunday, January 1, 2017 | 1935500000 | 9830000000 |
| Monday, January 1, 2018 | 2106300000 | 10102000000 |
| Tuesday, January 1, 2019 | 2374700000 | 10615000000 |
| Wednesday, January 1, 2020 | 2504500000 | 8955000000 |
| Friday, January 1, 2021 | 2674300000 | 9634000000 |
| Saturday, January 1, 2022 | 2403600000 | 10042000000 |
| Sunday, January 1, 2023 | 2549700000 | 10504000000 |
| Monday, January 1, 2024 | 2403700000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Merck & Co., Inc. and Biogen Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merck's SG&A expenses have shown a slight decline, averaging around $10 billion annually, with a notable dip in 2020. In contrast, Biogen's expenses have been more volatile, peaking in 2021 with a 38% increase from 2014. This divergence highlights Merck's consistent cost management strategies compared to Biogen's fluctuating operational expenditures. As the pharmaceutical landscape continues to shift, understanding these financial dynamics offers valuable insights into each company's strategic priorities and market positioning.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Bio-Techne Corporation
Comparing SG&A Expenses: Merck & Co., Inc. vs Amicus Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Arrowhead Pharmaceuticals, Inc.
Merck & Co., Inc. vs MannKind Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Dynavax Technologies Corporation
Merck & Co., Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: AstraZeneca PLC vs Biogen Inc.
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Biogen Inc.
Selling, General, and Administrative Costs: argenx SE vs Biogen Inc.
Cost Management Insights: SG&A Expenses for Biogen Inc. and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Biogen Inc. vs Wave Life Sciences Ltd.
SG&A Efficiency Analysis: Comparing Biogen Inc. and Ligand Pharmaceuticals Incorporated